A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Mylan, the profiteering, tax-dodging drug company currently taking immense heat for jacking up the price of its Epipen by 500%, announced Thursday that it will help more patients cover their ...

Mylan's generic version will hit shelves within several weeks at a list price of $300 for a two-pack carton in dosages of either 0.15 milligrams or 0.30 mg, the company said.

Mylan, which showered itself in infamy by jacking up the price of its EpiPen, a potentially life-saving epinephrine injector, by 500% over less than a decade, announced Friday that it is finally ...

Mylan Inc., based in suburban Pittsburgh, became Netherlands-based Mylan N.V. last year to reduce its U.S. income taxes. But when you take a close look at Mylan’s business, ...

Mylan on Monday said it would launch a generic alternative to EpiPen at a 50% discount after being criticized for dramatically raising the price of the lifesaving drug.

Mylan NV is poised to lose its hostile bid for Perrigo Co., people familiar with the matter said, a rare outcome in one of the bitterest takeover battles in decades.

When Mylan acquired EpiPen in 2007, the total market for epinephrine was around $207 million a year according to IMS Health. Even then, EpiPen was dominant, with its products accounting for nearly ...